melanotan 1 mt1 dosing recommendations 2 Dosage Chart by Skin Type MT1 (Melanotan 1) Dosage: 0.25–2
Description
European Journal of Biochemistry
DOI: 10.1016/j.peptides.2005.01.029 Clinical Development Afamelanotide and EPP Afamelanotide (MT-1), delivered as a subcutaneous slow-release implant, has been studied in multiple randomised controlled trials in patients with erythropoietic protoporphyria (EPP)
Some of the remaining double bonds are isomerized (to trans) in this operation
[PubMed] [Google Scholar] 97.Martins J, Steyn N, Rossouw HM, et al
